XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT)/EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive (loss)/income
Statutory reserve
Beginning balance (in shares) at Dec. 31, 2019   99,028,297        
Beginning balance at Dec. 31, 2019 $ (320,261) $ 6 $ 3,727 $ (320,760) $ (9,266) $ 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (33,625)     (33,625)    
Accretion for Series C1 Preferred (3,897)   (3,727) (170)    
Accretion for Series C2 Preferred (8,866)     (8,866)    
Accretion for Series D1 Preferred (18,648)     (18,648)    
Accretion for the exiting noncontrolling interests (5,668)     (5,668)    
Foreign currency translation adjustments 16,622       16,622  
Accretion of redeemable noncontrolling interests (10,259)     (10,259)    
Ending balance (in shares) at Dec. 31, 2020   99,028,297        
Ending balance at Dec. 31, 2020 (384,602) $ 6 0 (397,996) 7,356 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (206,483)     (206,483)    
Accretion for Series C1 Preferred (2,257)     (2,257)    
Accretion for Series C2 Preferred (5,132)     (5,132)    
Accretion for Series D1 Preferred (10,708)     (10,708)    
Accretion for redeemable noncontrolling interests (5,841)     (5,841)    
Accretion for the exiting noncontrolling interests (3,682)     (3,682)    
Issuance of common stock upon the reverse recapitalization, net of issuance costs (Note 3) (in shares)   191,254,950        
Issuance of common stock upon the reverse recapitalization, net of issuance costs (Note 3) 1,241,851 $ 23 1,241,828      
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred) (in shares)   8,559,769        
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred) 39,533 $ 1 39,532      
Share-based compensation(Note 22) 24,674   24,674      
Foreign currency translation adjustments (655)       (655)  
Ending balance (in shares) at Dec. 31, 2021   298,843,016        
Ending balance at Dec. 31, 2021 686,698 $ 30 1,306,034 (632,099) 6,701 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (158,200)     (158,200)    
Issuance of common stock in connection with vesting of share-based awards (in shares)   8,785,495        
Issuance of common stock in connection with vesting of share-based awards 0 $ 1 (1)      
Share-based compensation(Note 22) 110,127   110,127      
Foreign currency translation adjustments (24,782)       (24,782)  
Ending balance (in shares) at Dec. 31, 2022   307,628,511        
Ending balance at Dec. 31, 2022 $ 612,977 $ 31 $ 1,416,160 $ (791,165) $ (18,081) $ 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member]